Kathleen Borthwick sold $1,686 of PASG
CFO at Passage BIO, Inc.. 3,183 shares at an average of $0.53, traded Feb 11, 2025, filed Feb 12, 2025.
Score components
- +22RoleCFO
- 0Trade size$2k at market
- 0Share of holdings soldSold 7.2% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -25.6%, 3m -48.6%, 6m -38.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-003728, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 10, 2025 | MOption exercise Common Stock | +8,000 | - | - | 44,466 | Feb 12, 2025 |
| Feb 11, 2025 | SOpen-market sale Common Stock | -3,183 | $0.53 | $1,686 | 41,283 | Feb 12, 2025 |
| Feb 10, 2025 | MOption exercise Restricted Stock Unitderivative | -8,000 | $0.00 | $0 | 0 | Feb 12, 2025 |
Related signals
Other insiders at Passage BIO, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | PASGbuy Passage BIO, Inc. | Lynx1 Capital Management LP owner | $206k 50,055 shares | +8% | |
| 31Weak | Passage BIO, Inc. | Kathleen Borthwick CFO | $38k 2,062 shares | -28% | |
| 36Weak | Passage BIO, Inc. | William Chou PRESIDENT AND CEO | $75k 4,076 shares | -38% | |
| 35Weak | PASGbuy Passage BIO, Inc. | Lynx1 Capital Management LP owner | $224k 32,008 shares | +5% | |
| 52Moderate | PASGbuy Passage BIO, Inc. | Lynx1 Capital Management LP owner | $734k 128,848 shares | +28% | |
| 24Weak | PASGsell Passage BIO, Inc. | Orbimed Advisors LLC owner | $197k 583,657 shares | -9% | |
| 21Weak | PASGsell Passage BIO, Inc. | Orbimed Advisors LLC owner | $79k 235,572 shares | -3% | |
| 19Weak | PASGsell Passage BIO, Inc. | Orbimed Advisors LLC owner | $50k 149,054 shares | -2% | |
| 25Weak | PASGbuy Passage BIO, Inc. | Lynx1 Capital Management LP owner | $241k 373,645 shares | +4% | |
| 23Weak | PASGsell Passage BIO, Inc. | Orbimed Advisors LLC owner | $138k 230,321 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.